{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:49:28Z","timestamp":1793922568970,"version":"4.8.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41573-022-00421-7","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T12:33:41Z","timestamp":1647520421000},"page":"463-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["The promises and perils of psychedelic pharmacology for psychiatry"],"prefix":"10.1038","volume":"21","author":[{"given":"Tristan D.","family":"McClure-Begley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-6520","authenticated-orcid":false,"given":"Bryan L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"421_CR1","doi-asserted-by":"crossref","unstructured":"Hollister, L. E. Chemical Psychoses; LSD and Related Drugs (Thomas, 1968).","DOI":"10.1037\/009396"},{"key":"421_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","volume":"66","author":"H Osmond","year":"1957","unstructured":"Osmond, H. A review of the clinical effects of psychotomimetic agents. Ann. NY Acad. Sci. 66, 418\u2013434 (1957).","journal-title":"Ann. NY Acad. Sci."},{"key":"421_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols, D. E. Psychedelics. Pharmacol. Rev. 68, 264\u2013355 (2016).","journal-title":"Pharmacol. Rev."},{"key":"421_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0099-9598(01)56005-8","volume":"56","author":"KR Alper","year":"2001","unstructured":"Alper, K. R. Ibogaine: a review. Alkaloids Chem. Biol. 56, 1\u201338 (2001).","journal-title":"Alkaloids Chem. Biol."},{"key":"421_CR5","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1073\/pnas.182234399","volume":"99","author":"BL Roth","year":"2002","unstructured":"Roth, B. L. et al. Salvinorin A: a potent naturally occurring nonnitrogenous \u03ba opioid selective agonist. Proc. Natl Acad. Sci. USA 99, 11934\u201311939 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","volume":"115","author":"MW Johnson","year":"2011","unstructured":"Johnson, M. W., MacLean, K. A., Reissig, C. J., Prisinzano, T. E. & Griffiths, R. R. Human psychopharmacology and dose-effects of salvinorin A, a \u03ba opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 115, 150\u2013155 (2011).","journal-title":"Drug Alcohol Depend."},{"key":"421_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","volume":"11","author":"A Hoffman","year":"1979","unstructured":"Hoffman, A. How LSD originated. J. Psychedelic Drugs 11, 53\u201360 (1979).","journal-title":"J. Psychedelic Drugs"},{"key":"421_CR8","doi-asserted-by":"crossref","unstructured":"Fantegrossi, W. E. et al. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology 232, 1039\u20131047 (2015).","DOI":"10.1007\/s00213-014-3739-3"},{"key":"421_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12231-011-9152-5","volume":"65","author":"BP Akers","year":"2011","unstructured":"Akers, B. P., Ruiz, J. F., Piper, A. & Ruck, C. A. P. A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms? Economic Bot. 65, 121\u2013128 (2011).","journal-title":"Economic Bot."},{"key":"421_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nrl.2011.07.003","volume":"30","author":"FJ Carod-Artal","year":"2015","unstructured":"Carod-Artal, F. J. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia 30, 42\u201349 (2015).","journal-title":"Neurologia"},{"key":"421_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF01864855","volume":"34","author":"A Heffter","year":"1894","unstructured":"Heffter, A. Ueber Pellote. Ein Betrag zur pharmakologischen Kenntnis der Cacteen [German]. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 34, 65\u201386 (1894).","journal-title":"Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol."},{"key":"421_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF01825267","volume":"40","author":"A Heffter","year":"1898","unstructured":"Heffter, A. Uber peyote [German]. Naunyn Schmiedebergs Arch. Exp. Path. Pharmacol. 40, 385\u2013429 (1898).","journal-title":"Naunyn Schmiedebergs Arch. Exp. Path. Pharmacol."},{"key":"421_CR13","first-page":"163","volume":"20","author":"RG Wasson","year":"1963","unstructured":"Wasson, R. G. Notes on the present status of ololuiqui and the other hallucinogens of Mexico. Bot. Mus. Leafl. Harv. Univ. 20, 163\u2013193 (1963).","journal-title":"Bot. Mus. Leafl. Harv. Univ."},{"key":"421_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5962\/p.168538","volume":"20","author":"RG Wasson","year":"1962","unstructured":"Wasson, R. G. A new Mexican psychotropic drug from the mint family. Bot. Mus. Leafl. Harv. Univ. 20, 77\u201384 (1962).","journal-title":"Bot. Mus. Leafl. Harv. Univ."},{"key":"421_CR15","unstructured":"Abramson, H. A. The Use of LSD in Psychotherapy and Alcoholism (Bobbs-Merrill, 1967)."},{"key":"421_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1073\/pnas.40.4.228","volume":"40","author":"DW Wooley","year":"1954","unstructured":"Wooley, D. W. & Shaw, E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl Acad. Sci. USA 40, 228\u2013231 (1954).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR17","first-page":"758","volume":"187","author":"JO Cole","year":"1964","unstructured":"Cole, J. O. & Katz, M. M. The psychotomimetic drugs. An overview. JAMA 187, 758\u2013761 (1964).","journal-title":"JAMA"},{"key":"421_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1073\/pnas.40.4.228","volume":"40","author":"D Wooley","year":"1954","unstructured":"Wooley, D. & Shaw, E. A biochemical and pharmacological suggestion about certain mental disoders. Proc. Natl Acad. Sci. USA 40, 228\u2013231 (1954).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1476-5381.1954.tb00848.x","volume":"9","author":"JH Gaddum","year":"1954","unstructured":"Gaddum, J. H. & Hameed, K. A. Drugs which antagonize 5-hydroxytryptamine. Br. J. Pharmacol. Chemother. 9, 240\u2013248 (1954).","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"421_CR20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon, R. A., Titler, M. & McKenney, J. D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35, 2505\u20132511 (1984).","journal-title":"Life Sci."},{"key":"421_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF00176847","volume":"94","author":"M Titeler","year":"1988","unstructured":"Titeler, M., Lyon, R. A. & Glennon, R. A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site-of-action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94, 213\u2013216 (1988).","journal-title":"Psychopharmacology"},{"key":"421_CR22","unstructured":"Shulgin, A. T. & Shulgin, A. PIKHAL \u2014 A Chemical Love Story (Transform, 1991)."},{"key":"421_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1021\/jm00234a010","volume":"19","author":"RT Standridge","year":"1976","unstructured":"Standridge, R. T., Howell, H. G., Gylys, J. A., Partyka, R. A. & Shulgin, A. T. Phenylakylamines with potential psychotherapeutic utility: 1. 2-amino-1-(2,5-dimethoxy-4-methylphenyl)butane. J. Med. Chem. 19, 1400\u20131404 (1976).","journal-title":"J. Med. Chem."},{"key":"421_CR24","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1021\/jm00145a007","volume":"28","author":"DB Repke","year":"1985","unstructured":"Repke, D. B., Grotjahn, D. B. & Shulgin, A. T. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. J. Med. Chem. 28, 892\u2013896 (1985).","journal-title":"J. Med. Chem."},{"key":"421_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.2042-7158.1985.tb03072.x","volume":"37","author":"D Lemaire","year":"1985","unstructured":"Lemaire, D., Jacob, P. III & Shulgin, A. T. Ring-substituted \u03b2-methoxyphenethylamines: a new class of psychotomimetic agents active in man. J. Pharm. Pharmacol. 37, 575\u2013577 (1985).","journal-title":"J. Pharm. Pharmacol."},{"key":"421_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","volume":"128","author":"RH Porter","year":"1999","unstructured":"Porter, R. H. et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol. 128, 13\u201320 (1999).","journal-title":"Br. J. Pharmacol."},{"key":"421_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nsmb.3014","volume":"22","author":"WK Kroeze","year":"2015","unstructured":"Kroeze, W. K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362\u2013369 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"421_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","volume":"99","author":"A Rickli","year":"2015","unstructured":"Rickli, A. et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99, 546\u2013553 (2015).","journal-title":"Neuropharmacology"},{"key":"421_CR29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli, A., Moning, O. D., Hoener, M. C. & Liechti, M. E. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur. Neuropsychopharmacol. 26, 1327\u20131337 (2016).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"421_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1124\/jpet.115.229765","volume":"357","author":"LD Simmler","year":"2016","unstructured":"Simmler, L. D., Buchy, D., Chaboz, S., Hoener, M. C. & Liechti, M. E. In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J. Pharmacol. Exp. Ther. 357, 134\u2013144 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"421_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neuropharm.2008.08.003","volume":"56","author":"NM Barnes","year":"2009","unstructured":"Barnes, N. M., Hales, T. G., Lummis, S. C. & Peters, J. A. The 5-HT3 receptor \u2014 the relationship between structure and function. Neuropharmacology 56, 273\u2013284 (2009).","journal-title":"Neuropharmacology"},{"key":"421_CR32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","volume":"60","author":"JR Bunzow","year":"2001","unstructured":"Bunzow, J. R. et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 60, 1181\u20131188 (2001).","journal-title":"Mol. Pharmacol."},{"key":"421_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","volume":"462","author":"M Keiser","year":"2009","unstructured":"Keiser, M. et al. Predicting new molecular targets for known drugs. Nature 462, 175\u2013181 (2009).","journal-title":"Nature"},{"key":"421_CR34","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1021\/acschemneuro.8b00215","volume":"9","author":"BK Cassels","year":"2018","unstructured":"Cassels, B. K. & Saez-Briones, P. Dark classics in chemical neuroscience: mescaline. ACS Chem. Neurosci. 9, 2448\u20132458 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"421_CR35","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim, K. et al. Structure of a hallucinogen activated Gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574\u20131588.e19 (2020).","journal-title":"Cell"},{"key":"421_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1021\/cn400216u","volume":"5","author":"M Hansen","year":"2014","unstructured":"Hansen, M. et al. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A\/2C agonists. ACS Chem. Neurosci. 5, 243\u2013249 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"421_CR37","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1073\/pnas.182234399","volume":"99","author":"B Roth","year":"2002","unstructured":"Roth, B. et al. Salvinorin A: a potent naturally occurring nonnitrogenous \u03ba opioid selective agonist. Proc. Natl Acad. Sci. USA 99, 11934\u201311939 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0006-8993(95)00123-8","volume":"675","author":"SM Pearl","year":"1995","unstructured":"Pearl, S. M., Herrick-Davis, K., Teitler, M. & Glick, S. D. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Res. 675, 342\u2013344 (1995).","journal-title":"Brain Res."},{"key":"421_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.cell.2018.01.001","volume":"172","author":"Y Peng","year":"2018","unstructured":"Peng, Y. et al. 5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology. Cell 172, 719\u2013730.e14 (2018).","journal-title":"Cell"},{"key":"421_CR40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1126\/science.1232808","volume":"340","author":"D Wacker","year":"2013","unstructured":"Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615\u2013619 (2013).","journal-title":"Science"},{"key":"421_CR41","first-page":"924","volume":"246","author":"E Sanders-Bush","year":"1988","unstructured":"Sanders-Bush, E., Burris, K. D. & Knoth, K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J. Pharmacol. Exp. Ther. 246, 924\u2013928 (1988).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"421_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonzalez-Maeso","year":"2007","unstructured":"Gonzalez-Maeso, J. et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 53, 439\u2013452 (2007).","journal-title":"Neuron"},{"key":"421_CR43","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082","volume":"7","author":"KH Preller","year":"2018","unstructured":"Preller, K. H. et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife 7, e35082 (2018).","journal-title":"eLife"},{"key":"421_CR44","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","volume":"33","author":"M Kometer","year":"2013","unstructured":"Kometer, M., Schmidt, A., Jancke, L. & Vollenweider, F. X. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations. J. Neurosci. 33, 10544\u201310551 (2013).","journal-title":"J. Neurosci."},{"key":"421_CR45","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/jcbfm.2014.68","volume":"34","author":"A Ettrup","year":"2014","unstructured":"Ettrup, A. et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. J. Cereb. Blood Flow Metab. 34, 1188\u20131196 (2014).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"421_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(199709)27:1<79::AID-SYN8>3.0.CO;2-A","volume":"27","author":"D Willins","year":"1997","unstructured":"Willins, D., Deutch, A. & Roth, B. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27, 79\u201382 (1997).","journal-title":"Synapse"},{"key":"421_CR47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1073\/pnas.95.2.735","volume":"95","author":"R Jakab","year":"1998","unstructured":"Jakab, R. & Goldman-Rakic, P. 5-hydroxytryptamine 2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl Acad. Sci. USA 95, 735\u2013740 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR48","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","volume":"36","author":"GK Aghajanian","year":"1997","unstructured":"Aghajanian, G. K. & Marek, G. J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36, 589\u2013599 (1997).","journal-title":"Neuropharmacology"},{"key":"421_CR49","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/0028-3908(84)90244-2","volume":"23","author":"B Roth","year":"1984","unstructured":"Roth, B. L., Nakaki, T., Chuang, D. M. & Costa, E. Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology 23, 1223\u20131225 (1984).","journal-title":"Neuropharmacology"},{"key":"421_CR50","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0028-3908(84)90017-0","volume":"23","author":"PJ Conn","year":"1984","unstructured":"Conn, P. J. & Sanders-Bush, E. Selective 5-HT2 antagonists inhibit serotonin-stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 23, 993\u2013996 (1984).","journal-title":"Neuropharmacology"},{"key":"421_CR51","first-page":"480","volume":"238","author":"BL Roth","year":"1986","unstructured":"Roth, B. L., Nakaki, T., Chuang, D. M. & Costa, E. 5-hydroxytryptamine 2 receptors coupled to phospholipase C in rat aorta \u2014 modulation of phosphoinositide turnover by phorbol ester. J. Pharmacol. Exp. Ther. 238, 480\u2013485 (1986).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"421_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41594-019-0252-8","volume":"26","author":"BL Roth","year":"2019","unstructured":"Roth, B. L. Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. Nat. Struct. Mol. Biol. 26, 535\u2013544 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"421_CR53","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1046\/j.1471-4159.1999.0722206.x","volume":"72","author":"E Gelber","year":"1999","unstructured":"Gelber, E. et al. Structure and function of the third intracellular loop of the 5-hydroxytryptamine 2A receptor: the third intracellular loop is \u03b1-helical and binds purified arrestins. J. Neurochem. 72, 2206\u20132214 (1999).","journal-title":"J. Neurochem."},{"key":"421_CR54","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1124\/mol.63.5.961","volume":"63","author":"J Gray","year":"2003","unstructured":"Gray, J., Bhatnagar, A., Gurevich, V. & Roth, B. The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT2A receptor induces agonist-independent internalization. Mol. Pharmacol. 63, 961\u2013972 (2003).","journal-title":"Mol. Pharmacol."},{"key":"421_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","volume":"168","author":"D Wacker","year":"2017","unstructured":"Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377\u2013389.e12 (2017).","journal-title":"Cell"},{"key":"421_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1073\/pnas.0708862105","volume":"105","author":"CL Schmid","year":"2008","unstructured":"Schmid, C. L., Raehal, K. M. & Bohn, L. M. Agonist-directed signaling of the serotonin 2A receptor depends on \u03b2-arrestin-2 interactions in vivo. Proc. Natl Acad. Sci. USA 105, 1079\u20131084 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR57","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.1523\/JNEUROSCI.1665-10.2010","volume":"30","author":"CL Schmid","year":"2010","unstructured":"Schmid, C. L. & Bohn, L. M. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2\/Src\/Akt signaling complex in vivo. J. Neurosci. 30, 13513\u201313524 (2010).","journal-title":"J. Neurosci."},{"key":"421_CR58","doi-asserted-by":"publisher","first-page":"17690","DOI":"10.1038\/s41598-021-96736-3","volume":"11","author":"RM Rodriguez","year":"2021","unstructured":"Rodriguez, R. M. et al. LSD-stimulated behaviors in mice require \u03b2-arrestin 2 but not \u03b2-arrestin 1. Sci. Rep. 11, 17690 (2021).","journal-title":"Sci. Rep."},{"key":"421_CR59","doi-asserted-by":"publisher","first-page":"114251","DOI":"10.1016\/j.bcp.2020.114251","volume":"182","author":"E Pottie","year":"2020","unstructured":"Pottie, E., Dedecker, P. & Stove, C. P. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of \u03b2-arrestin 2 and miniGalphaq bioassays. Biochem. Pharmacol. 182, 114251 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"421_CR60","first-page":"277","volume":"45","author":"MP Johnson","year":"1994","unstructured":"Johnson, M. P., Loncharich, R. J., Baez, M. & Nelson, D. L. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure\u2013activity relationship of certain ergolines and tryptamines. Mol. Pharmacol. 45, 277\u2013286 (1994).","journal-title":"Mol. Pharmacol."},{"key":"421_CR61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"BL Roth","year":"2007","unstructured":"Roth, B. L. Drugs and valvular heart disease. N. Engl. J. Med. 356, 6\u20139 (2007).","journal-title":"N. Engl. J. Med."},{"key":"421_CR62","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"R Rothman","year":"2000","unstructured":"Rothman, R. et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836\u20132841 (2000).","journal-title":"Circulation"},{"key":"421_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581\u2013588 (1997).","journal-title":"N. Engl. J. Med."},{"key":"421_CR64","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJM199809103391109","volume":"339","author":"RB Devereux","year":"1998","unstructured":"Devereux, R. B. Appetite suppressants and valvular heart disease. N. Engl. J. Med. 339, 765\u2013766 (1998).","journal-title":"N. Engl. J. Med."},{"key":"421_CR65","first-page":"6","volume":"44","author":"AL Salner","year":"1980","unstructured":"Salner, A. L., Mullany, L. D. & Cole, S. R. Methysergide induced mitral valvular insufficiency. Conn. Med. 44, 6\u20138 (1980).","journal-title":"Conn. Med."},{"key":"421_CR66","first-page":"235","volume":"5","author":"M Hendrikx","year":"1996","unstructured":"Hendrikx, M., Van Dorpe, J., Flameng, W. & Daenen, W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J. Heart Valve Dis. 5, 235\u2013237 (1996).","journal-title":"J. Heart Valve Dis."},{"key":"421_CR67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini, R. et al. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N. Engl. J. Med. 356, 39\u201346 (2007).","journal-title":"N. Engl. J. Med."},{"key":"421_CR68","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","volume":"63","author":"V Setola","year":"2003","unstructured":"Setola, V. et al. 3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223\u20131229 (2003).","journal-title":"Mol. Pharmacol."},{"key":"421_CR69","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","volume":"100","author":"S Droogmans","year":"2007","unstructured":"Droogmans, S. et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am. J. Cardiol. 100, 1442\u20131445 (2007).","journal-title":"Am. J. Cardiol."},{"key":"421_CR70","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1365-2125.2012.04252.x","volume":"74","author":"F Montastruc","year":"2012","unstructured":"Montastruc, F. et al. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, \u2018Ecstasy\u2019). Br. J. Clin. Pharmacol. 74, 547\u2013548 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"421_CR71","first-page":"1140","volume":"105","author":"JH Fortier","year":"2019","unstructured":"Fortier, J. H. et al. Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis. Heart 105, 1140\u20131148 (2019).","journal-title":"Heart"},{"key":"421_CR72","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1124\/jpet.107.133348","volume":"325","author":"WJ Thomsen","year":"2008","unstructured":"Thomsen, W. J. et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325, 577\u2013587 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"421_CR73","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith, S. R. et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245\u2013256 (2010).","journal-title":"N. Engl. J. Med."},{"key":"421_CR74","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus, E., Kometer, M., Hasler, F. & Vollenweider, F. X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J. Psychopharmacol. 25, 1434\u20131452 (2011).","journal-title":"J. Psychopharmacol."},{"key":"421_CR75","doi-asserted-by":"publisher","first-page":"113638","DOI":"10.1016\/j.expneurol.2021.113638","volume":"339","author":"F Schifano","year":"2021","unstructured":"Schifano, F. et al. New psychoactive substances (NPS) and serotonin syndrome onset: a systematic review. Exp. Neurol. 339, 113638 (2021).","journal-title":"Exp. Neurol."},{"key":"421_CR76","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0749-0704(05)70368-7","volume":"13","author":"KC Mills","year":"1997","unstructured":"Mills, K. C. Serotonin syndrome. A clinical update. Crit. Care Clin. 13, 763\u2013783 (1997).","journal-title":"Crit. Care Clin."},{"key":"421_CR77","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMra041867","volume":"352","author":"EW Boyer","year":"2005","unstructured":"Boyer, E. W. & Shannon, M. The serotonin syndrome. N. Engl. J. Med. 352, 1112\u20131120 (2005).","journal-title":"N. Engl. J. Med."},{"key":"421_CR78","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/dta.1333","volume":"4","author":"CE Canal","year":"2012","unstructured":"Canal, C. E. & Morgan, D. Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test. Anal. 4, 556\u2013576 (2012).","journal-title":"Drug Test. Anal."},{"key":"421_CR79","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0149-7634(82)90036-7","volume":"6","author":"JB Appel","year":"1982","unstructured":"Appel, J. B., White, F. J. & Holohean, A. M. Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures. Neurosci. Biobehav. Rev. 6, 529\u2013536 (1982).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"421_CR80","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0166-4328(85)90090-7","volume":"16","author":"EB Nielsen","year":"1985","unstructured":"Nielsen, E. B., Ginn, S. R., Cunningham, K. A. & Appel, J. B. Antagonism of the LSD cue by putative serotonin antagonists: relationship to inhibition of in vivo [3H]spiroperidol binding. Behav. Brain Res. 16, 171\u2013176 (1985).","journal-title":"Behav. Brain Res."},{"key":"421_CR81","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1126\/science.7071600","volume":"216","author":"FJ White","year":"1982","unstructured":"White, F. J. & Appel, J. B. Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions. Science 216, 535\u2013537 (1982).","journal-title":"Science"},{"key":"421_CR82","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/BF00435266","volume":"76","author":"J Koerner","year":"1982","unstructured":"Koerner, J. & Appel, J. B. Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for \u2018hallucinogens\u2019. Psychopharmacology 76, 130\u2013135 (1982).","journal-title":"Psychopharmacology"},{"key":"421_CR83","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00690929","volume":"91","author":"KA Cunningham","year":"1987","unstructured":"Cunningham, K. A. & Appel, J. B. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacology 91, 67\u201373 (1987).","journal-title":"Psychopharmacology"},{"key":"421_CR84","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","volume":"91","author":"RA Glennon","year":"1983","unstructured":"Glennon, R. A., Young, R. & Rosencrans, J. A. Antagonism of the effects of the hallucinogen DOM, and the purported 5-HT agonist quipazine, by 5-HT2 antagonists. Eur. Pharm. 91, 189\u2013193 (1983).","journal-title":"Eur. Pharm."},{"key":"421_CR85","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/BF02246164","volume":"119","author":"D Fiorella","year":"1995","unstructured":"Fiorella, D., Rabin, R. A. & Winter, J. C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology 119, 222\u2013230 (1995).","journal-title":"Psychopharmacology"},{"key":"421_CR86","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","volume":"167","author":"AL Halberstadt","year":"2020","unstructured":"Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J. & Brandt, S. D. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 167, 107933 (2020).","journal-title":"Neuropharmacology"},{"key":"421_CR87","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1126\/science.124.3225.723","volume":"124","author":"DL Keller","year":"1956","unstructured":"Keller, D. L. & Umbreit, W. W. Permanent alteration of behavior in mice by chemical and psychological means. Science 124, 723\u2013724 (1956).","journal-title":"Science"},{"key":"421_CR88","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00401509","volume":"11","author":"SJ Corne","year":"1967","unstructured":"Corne, S. J. & Pickering, R. W. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia 11, 65\u201378 (1967).","journal-title":"Psychopharmacologia"},{"key":"421_CR89","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF00429548","volume":"42","author":"MT Silva","year":"1975","unstructured":"Silva, M. T. & Calil, H. M. Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia 42, 163\u2013171 (1975).","journal-title":"Psychopharmacologia"},{"key":"421_CR90","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1093\/cercor\/bhx257","volume":"28","author":"FS Barrett","year":"2018","unstructured":"Barrett, F. S., Preller, K. H., Herdener, M., Janata, P. & Vollenweider, F. X. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb. Cortex 28, 3939\u20133950 (2018).","journal-title":"Cereb. Cortex"},{"key":"421_CR91","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze, F. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 46, 537\u2013544 (2021).","journal-title":"Neuropsychopharmacology"},{"key":"421_CR92","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Babler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897\u20133902 (1998).","journal-title":"Neuroreport"},{"key":"421_CR93","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1523\/JNEUROSCI.1090-09.2009","volume":"29","author":"A Abbas","year":"2009","unstructured":"Abbas, A. et al. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J. Neurosci. 29, 7124\u20137136 (2009).","journal-title":"J. Neurosci."},{"key":"421_CR94","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1476-5381.1963.tb01302.x","volume":"20","author":"SJ Corne","year":"1963","unstructured":"Corne, S. J., Pickering, R. W. & Warner, B. T. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br. J. Pharmacol. Chemother. 20, 106\u2013120 (1963).","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"421_CR95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/7854_2016_466","volume":"36","author":"AL Halberstadt","year":"2017","unstructured":"Halberstadt, A. L. & Geyer, M. A. Effect of hallucinogens on unconditioned behavior. Curr. Top. Behav. Neurosci. 36, 159\u2013199 (2017).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"421_CR96","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1523\/JNEUROSCI.1090-09.2009","volume":"29","author":"AI Abbas","year":"2009","unstructured":"Abbas, A. I. et al. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J. Neurosci. 29, 7124\u20137136 (2009).","journal-title":"J. Neurosci."},{"key":"421_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2011.35","volume":"1","author":"JA Allen","year":"2011","unstructured":"Allen, J. A., Yadav, P. N., Setola, V., Farrell, M. & Roth, B. L. Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo. Transl. Psych. 1, e33 (2011).","journal-title":"Transl. Psych."},{"key":"421_CR98","doi-asserted-by":"publisher","first-page":"19575","DOI":"10.1073\/pnas.0905884106","volume":"106","author":"K Jones","year":"2009","unstructured":"Jones, K. et al. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc. Natl Acad. Sci. USA 106, 19575\u201319580 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR99","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly, C. et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 23, 3170\u20133182 (2018).","journal-title":"Cell Rep."},{"key":"421_CR100","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/ijms22020835","volume":"22","author":"NR Raval","year":"2021","unstructured":"Raval, N. R. et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int. J. Mol. Sci. 22, 835 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"421_CR101","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","volume":"62","author":"RS Duman","year":"2012","unstructured":"Duman, R. S., Li, N., Liu, R. J., Duric, V. & Aghajanian, G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62, 35\u201341 (2012).","journal-title":"Neuropharmacology"},{"key":"421_CR102","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0896-6273(03)00195-8","volume":"38","author":"JT Coyle","year":"2003","unstructured":"Coyle, J. T. & Duman, R. S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38, 157\u2013160 (2003).","journal-title":"Neuron"},{"key":"421_CR103","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neuron.2020.05.015","volume":"106","author":"ET Kavalali","year":"2020","unstructured":"Kavalali, E. T. & Monteggia, L. M. Targeting homeostatic synaptic plasticity for treatment of mood disorders. Neuron 106, 715\u2013726 (2020).","journal-title":"Neuron"},{"key":"421_CR104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","volume":"16","author":"RHJ Olsen","year":"2020","unstructured":"Olsen, R. H. J. et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat. Chem. Biol. 16, 841\u2013849 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"421_CR105","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","volume":"172","author":"T Che","year":"2018","unstructured":"Che, T. et al. Structure of the nanobody-stabilized active state of the \u03ba opioid receptor. Cell 172, 55\u201367.e15 (2018).","journal-title":"Cell"},{"key":"421_CR106","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-019-1135-1","volume":"569","author":"JA Coleman","year":"2019","unstructured":"Coleman, J. A. et al. Serotonin transporter\u2013ibogaine complexes illuminate mechanisms of inhibition and transport. Nature 569, 141\u2013145 (2019).","journal-title":"Nature"},{"key":"421_CR107","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt, D., Erritzoe, D. & Carhart-Harris, R. Psychedelic psychiatry\u2019s brave new world. Cell 181, 24\u201328 (2020).","journal-title":"Cell"},{"key":"421_CR108","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"key":"421_CR109","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"421_CR110","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402\u20131411 (2021).","journal-title":"N. Engl. J. Med."},{"key":"421_CR111","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399\u2013408 (2018).","journal-title":"Psychopharmacology"},{"key":"421_CR112","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff, C. M. et al. Psychedelics and psychedelic-assisted psychotherapy. Am. J. Psychiatry 177, 391\u2013410 (2020).","journal-title":"Am. J. Psychiatry"},{"key":"421_CR113","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1177\/0269881116675771","volume":"30","author":"JD McCorvy","year":"2016","unstructured":"McCorvy, J. D., Olsen, R. H. & Roth, B. L. Psilocybin for depression and anxiety associated with life-threatening illnesses. J. Psychopharmacol. 30, 1209\u20131210 (2016).","journal-title":"J. Psychopharmacol."},{"key":"421_CR114","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fpsyt.2018.00293","volume":"9","author":"JM Barnby","year":"2018","unstructured":"Barnby, J. M. & Mehta, M. A. Psilocybin and mental health \u2014 don\u2019t lose control. Front Psychiatry 9, 293 (2018).","journal-title":"Front Psychiatry"},{"key":"421_CR115","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol."},{"key":"421_CR116","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2020","unstructured":"Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481\u2013489 (2020).","journal-title":"JAMA Psychiatry"},{"key":"421_CR117","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"KR Bonson","year":"1996","unstructured":"Bonson, K. R., Buckholtz, J. W. & Murphy, D. L. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14, 425\u2013436 (1996).","journal-title":"Neuropsychopharmacology"},{"key":"421_CR118","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","volume":"73","author":"KR Bonson","year":"1996","unstructured":"Bonson, K. R. & Murphy, D. L. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav. Brain Res. 73, 229\u2013233 (1996).","journal-title":"Behav. Brain Res."},{"key":"421_CR119","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"421_CR120","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.tpj.6500342","volume":"6","author":"MA Davies","year":"2005","unstructured":"Davies, M. A. et al. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 6, 42\u201351 (2005).","journal-title":"Pharmacogenomics J."},{"key":"421_CR121","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0893-133X(00)00223-2","volume":"24","author":"CM Niswender","year":"2001","unstructured":"Niswender, C. M. et al. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 24, 478\u2013491 (2001).","journal-title":"Neuropsychopharmacology"},{"key":"421_CR122","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acsptsci.0c00176","volume":"4","author":"AK Klein","year":"2021","unstructured":"Klein, A. K. et al. Investigation of the structure\u2013activity relationships of psilocybin analogues. ACS Pharmacol. Transl. Sci. 4, 533\u2013542 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"421_CR123","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman, L., Nutt, D. J. & Carhart-Harris, R. L. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol. 8, 974 (2017).","journal-title":"Front. Pharmacol."},{"key":"421_CR124","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/7854_2017_474","volume":"36","author":"FS Barrett","year":"2018","unstructured":"Barrett, F. S. & Griffiths, R. R. Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr. Top. Behav. Neurosci. 36, 393\u2013430 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"421_CR125","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen, M. K. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44, 1328\u20131334 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"421_CR126","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B. & Thompson, S. M. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc. Natl Acad. Sci. USA 118, e2022489118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"421_CR127","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/sj.npp.1301638","volume":"33","author":"P Conn","year":"2008","unstructured":"Conn, P. & Roth, B. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33, 2048\u20132060 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"421_CR128","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron, L. P. et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589, 474\u2013479 (2021).","journal-title":"Nature"},{"key":"421_CR129","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.cell.2021.03.043","volume":"184","author":"C Dong","year":"2021","unstructured":"Dong, C. et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell 184, 2779\u20132792.e18 (2021).","journal-title":"Cell"},{"key":"421_CR130","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","volume":"566","author":"J Lyu","year":"2019","unstructured":"Lyu, J. et al. Ultra-large library docking for discovering new chemotypes. Nature 566, 224\u2013229 (2019).","journal-title":"Nature"},{"key":"421_CR131","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2027-0","volume":"579","author":"RM Stein","year":"2020","unstructured":"Stein, R. M. et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Natur 579, 609\u2013614 (2020).","journal-title":"Natur"},{"key":"421_CR132","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2017.07.009","volume":"170","author":"D Wacker","year":"2017","unstructured":"Wacker, D., Stevens, R. C. & Roth, B. L. How ligands illuminate GPCR molecular pharmacology. Cell 170, 414\u2013427 (2017).","journal-title":"Cell"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00421-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T09:08:32Z","timestamp":1654506512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00421-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":132,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1038\/s41573-022-00421-7","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"4 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}